Cargando…
A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer
BACKGROUND: Lung cancer is the leading cause of cancer-related death in the United States. Nearly 50% of patients with stages I and II non-small cell lung cancer (NSCLC) will die from recurrent disease despite surgical resection. No reliable clinical or molecular predictors are currently available f...
Autores principales: | Lu, Yan, Lemon, William, Liu, Peng-Yuan, Yi, Yijun, Morrison, Carl, Yang, Ping, Sun, Zhifu, Szoke, Janos, Gerald, William L, Watson, Mark, Govindan, Ramaswamy, You, Ming |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1716187/ https://www.ncbi.nlm.nih.gov/pubmed/17194181 http://dx.doi.org/10.1371/journal.pmed.0030467 |
Ejemplares similares
-
Gene-Expression Signature Predicts Postoperative Recurrence in Stage I Non-Small Cell Lung Cancer Patients
por: Lu, Yan, et al.
Publicado: (2012) -
Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer
por: Scagliotti, Giorgio, et al.
Publicado: (2010) -
Management of patients with advanced non-small cell lung cancer: role of gefitinib
por: Velcheti, Vamsidhar, et al.
Publicado: (2010) -
Matrix Metallopeptidase-Gene Signature Predicts Stage I Lung Adenocarcinoma Survival Outcomes
por: Liu, Chia-Hsin, et al.
Publicado: (2023) -
Bone metastases in non-small cell lung cancer: a narrative review
por: Knapp, Brendan J., et al.
Publicado: (2022)